Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma*
暂无分享,去创建一个
Douglas B. Johnson | J. Balko | D. Liebler | L. Zimmerman | Carlos A. Morales-Betanzos | Hyoun-Kyoung Lee | P. G. González Ericsson
[1] Ruchi Verma,et al. A Support Vector Machine based method to distinguish proteobacterial proteins from eukaryotic plant proteins , 2012, BMC Bioinformatics.
[2] P. Robbins,et al. Separation of Glycopeptides by High Performance Liquid Chromatography , 1982, Journal of cellular biochemistry.
[3] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[4] I. Ganly,et al. Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] G. Gao,et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy , 2016, Cell Research.
[6] Michael J MacCoss,et al. Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma* , 2015, Molecular & Cellular Proteomics.
[7] Jamey D. Young,et al. Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer * , 2016, Molecular & Cellular Proteomics.
[8] P. Massion,et al. Methods for Peptide and Protein Quantitation by Liquid Chromatography-Multiple Reaction Monitoring Mass Spectrometry* , 2011, Molecular & Cellular Proteomics.
[9] R. Noelle,et al. VISTA Regulates the Development of Protective Antitumor Immunity. , 2014, Cancer research.
[10] Xinning Jiang,et al. Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. , 2009, Journal of proteome research.
[11] A. Anderson. Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape , 2014, Cancer Immunology Research.
[12] Hoguen Kim,et al. Abundance-ratio-based semiquantitative analysis of site-specific N-linked glycopeptides present in the plasma of hepatocellular carcinoma patients. , 2014, Journal of proteome research.
[13] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[14] P. Sharma,et al. Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.
[15] D. Liebler,et al. Assembly Dynamics and Stoichiometry of the Apoptosis Signal-regulating Kinase (ASK) Signalosome in Response to Electrophile Stress* , 2016, Molecular & Cellular Proteomics.
[16] D. Fearon,et al. T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.
[17] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[18] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[19] A. Borczuk,et al. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. , 2016, Archives of pathology & laboratory medicine.
[20] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[21] Rony Dahan,et al. Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. , 2016, Cancer cell.
[22] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[23] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[24] J. Taube,et al. PD-1/PD-L1 inhibitors. , 2015, Current opinion in pharmacology.
[25] G. Gao,et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab , 2017, Nature Communications.
[26] L. Sempere,et al. VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy , 2014, Cancer Immunology Research.
[27] P. Sharma,et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.
[28] Brendan MacLean,et al. Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .
[29] Deepak R. Mani,et al. Statistical characterization of multiple-reaction monitoring mass spectrometry (MRM-MS) assays for quantitative proteomics , 2012, BMC Bioinformatics.
[30] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[31] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[32] Yu Shyr,et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.
[33] M. Valsecchi. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.
[34] M. Washington,et al. Precision of Multiple Reaction Monitoring Mass Spectrometry Analysis of Formalin-Fixed, Paraffin-Embedded Tissue , 2012, Journal of proteome research.
[35] L. Nguyen,et al. Clinical blockade of PD1 and LAG3 — potential mechanisms of action , 2014, Nature Reviews Immunology.
[36] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[37] Maria P. Pavlou,et al. Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay* , 2012, Molecular & Cellular Proteomics.
[38] G. Freeman,et al. Combination cancer immunotherapy and new immunomodulatory targets , 2015, Nature Reviews Drug Discovery.
[39] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[40] Christoph H Borchers,et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma , 2009, Nature Biotechnology.
[41] C. Paweletz,et al. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. , 2016, JCI insight.
[42] J. Taube,et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.
[43] Drew M Pardoll,et al. Differential binding properties of B7-H1 and B7-DC to programmed death-1. , 2003, Biochemical and biophysical research communications.
[44] Ronald J. Moore,et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum , 2012, Proceedings of the National Academy of Sciences.
[45] D. Olive,et al. A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage , 2015, Oncoimmunology.
[46] Drew M. Pardoll,et al. The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.
[47] J. Lunceford,et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] K. Zak,et al. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1. , 2015, Structure.
[49] Jun Yao,et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity , 2016, Nature Communications.
[50] Ludmila V. Danilova,et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors , 2016, Proceedings of the National Academy of Sciences.
[51] D. Liebler,et al. Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays* , 2015, Molecular & Cellular Proteomics.
[52] T. Schumacher,et al. Neoantigens in cancer immunotherapy , 2015, Science.
[53] Richard Z. Liu,et al. Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. , 2010, Journal of proteome research.
[54] W. Wick,et al. Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors , 2015, Front. Immunol..
[55] Jedd D. Wolchok,et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.
[56] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[57] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[58] Derek J. Bailey,et al. Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.
[59] Christoph H Borchers,et al. Design, Implementation and Multisite Evaluation of a System Suitability Protocol for the Quantitative Assessment of Instrument Performance in Liquid Chromatography-Multiple Reaction Monitoring-MS (LC-MRM-MS)* , 2013, Molecular & Cellular Proteomics.
[60] B. Domon,et al. Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.
[61] G. Freeman,et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.